Boston Scientific Corporation

Boston Scientific Corporation

BSX-PA

Get informed when a big investor buys or sells

+ Follow
Market Cap$175.45B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Boston Scientific CorporationBoston Scientific Corporation18.9-14%9.40.4

Earnings Call Q1 2026

April 22, 2026 - AI Summary

First Quarter Performance: Boston Scientific reported organic sales growth of 9.4% in Q1 2026, achieving the high end of its guidance range, with adjusted EPS of $0.80 reflecting a 6% year-over-year increase. This performance was largely driven by significant growth in regions like the U.S. (11%) and Asia Pacific (12%).
Revised Guidance: The company has lowered its full-year organic revenue growth forecast to 6.5% to 8% (previously 8% to 10%) and expects Q2 2026 organic growth of 5% to 7%, citing unanticipated headwinds primarily from decreased growth rates in key segments including EP, WATCHMAN, and Urology.
Segment Challenges: The key challenges impacting growth involve the WATCHMAN business, where volumes have declined due to changes in physician practice patterns, particularly a shift towards concomitant procedures over standalone implants. The Urology segment, notably affected by competition and product gaps, is anticipated to grow only low to mid-single digits in 2026.

Exclusive for Stockcircle Pro members

Sign upSign Up

Share Statistics

Market cap$175.45 Billion
Enterprise Value$184.95 Billion
Dividend Yield$5.50 (-)
Earnings per Share$1.96
Beta0.8
Outstanding Shares1,484,900,000

Return

Return on Equity13.75%ROE
Return on Assets8.02%
Return on Invested Capital9.40%

Valuation & Multiples

P/E Ratio18.87P/E Ratio
PEG19.18PEG
Price to Sales9.4Price to Sales
Price to Book Ratio7.19Price to Book Ratio
Enterprise Value to Revenue8.97
Enterprise Value to EBIT49.44
Enterprise Value to Net Income51
Total Debt to Enterprise0.06
Debt to Equity0.43Debt to Equity

Revenue Sources

No data

Insider Trades

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

ESG Score

No data

About Boston Scientific Corporation

45,000 employees
CEO: Michael F. Mahoney

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The com...

Relevant Senate Committees

Joint Committee on Taxation

Determines tax policy on medical devices and R&D credits, which significantly impacts the company's financial performance and capital allocation.

Finance

Controls Medicare and Medicaid reimbursement policy, the single largest driver of revenue and pricing for medical device companies.

Appropriations

Determines the actual funding levels for healthcare agencies and research grants, providing members with non-public knowledge of future government spending.

Health, Education, Labor, and Pensions

Directly regulates the FDA, which controls the approval process for all of the company's medical technologies.

Special Committee on Aging

The committee's focus on Medicare and conditions affecting the elderly directly aligns with Boston Scientific's core cardiac and neuro patient demographics.

Veterans' Affairs

The VA is a major purchaser of cardiovascular and surgical devices; committee decisions directly impact the company's revenue from the public sector.